William C. Gruber
About
William C. Gruber is a scholar working on Epidemiology, Microbiology and Infectious Diseases.
According to data from OpenAlex, William C. Gruber has authored 232 papers receiving a total of 12.4k indexed citations (citations by other indexed papers that have themselves been cited), including 206 papers in Epidemiology, 69 papers in Microbiology and 42 papers in Infectious Diseases. Recurrent topics in William C. Gruber's work include Respiratory viral infections research (147 papers), Pneumonia and Respiratory Infections (146 papers) and Bacterial Infections and Vaccines (67 papers). William C. Gruber is often cited by papers focused on Respiratory viral infections research (147 papers), Pneumonia and Respiratory Infections (146 papers) and Bacterial Infections and Vaccines (67 papers). William C. Gruber collaborates with scholars based in United States, Germany and United Kingdom. William C. Gruber's co-authors include Anne Shumway‐Cook, Margaret Baldwin, Daniel A. Scott, Nayak L. Polissar, Robert B. Belshe, Emilio A. Emini, Kathrin U. Jansen, Alejandra Gurtman, Pedro A. Piedra and Beate Schmöele-Thoma and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Blood.
In The Last Decade
William C. Gruber
222 papers receiving 11.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| William C. Gruber United States | 58 | 9.3k | 2.7k | 1.7k | 1.3k | 1.3k | 232 | 12.4k | ||
| Michael D. Decker United States | 40 | 3.9k 0.4× | 1.2k 0.5× | 2.2k 1.3× | 489 0.4× | 121 0.1× | 168 | 6.2k | ||
| André Charlett United Kingdom | 51 | 2.6k 0.3× | 3.3k 1.2× | 287 0.2× | 349 0.3× | 92 0.1× | 275 | 9.7k | ||
| Marek Smieja Canada | 45 | 3.4k 0.4× | 3.3k 1.2× | 749 0.4× | 631 0.5× | 12 0.0× | 203 | 8.5k | ||
| William C. Blackwelder United States | 48 | 2.9k 0.3× | 1.7k 0.6× | 1.2k 0.7× | 566 0.4× | 8 0.0× | 125 | 8.8k | ||
| Janet E. McElhaney Canada | 49 | 4.9k 0.5× | 1.3k 0.5× | 147 0.1× | 2.6k 2.0× | 17 0.0× | 168 | 9.1k | ||
| Charles G. Prober United States | 39 | 3.5k 0.4× | 1.5k 0.6× | 257 0.1× | 294 0.2× | 24 0.0× | 133 | 6.6k | ||
| B. Frank Polk United States | 46 | 3.6k 0.4× | 2.7k 1.0× | 267 0.2× | 673 0.5× | 12 0.0× | 93 | 9.2k | ||
| Adrian Egli Switzerland | 38 | 1.7k 0.2× | 1.6k 0.6× | 149 0.1× | 734 0.6× | 40 0.0× | 281 | 6.3k | ||
| Donald P. Kotler United States | 62 | 2.9k 0.3× | 4.3k 1.6× | 126 0.1× | 1.7k 1.3× | 17 0.0× | 236 | 14.4k | ||
| Noelle‐Angelique Molinari United States | 23 | 1.8k 0.2× | 813 0.3× | 53 0.0× | 223 0.2× | 109 0.1× | 57 | 3.5k |
Countries citing papers authored by William C. Gruber
Since
Specialization
Citations
This map shows the geographic impact of William C. Gruber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William C. Gruber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William C. Gruber more than expected).
Fields of papers citing papers by William C. Gruber
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by William C. Gruber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William C. Gruber. The network helps show where William C. Gruber may publish in the future.
Co-authorship network of co-authors of William C. Gruber
This figure shows the co-authorship network connecting the top 25 collaborators of William C. Gruber. A scholar is included among the top collaborators of William C. Gruber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William C. Gruber. William C. Gruber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Martinón‐Torres, Federico, James Trammel, Yahong Peng, et al.. (2025). A phase 3 study of 20-valent pneumococcal conjugate vaccine in healthy toddlers previously vaccinated in infancy with 13-valent pneumococcal conjugate vaccine. Vaccine. 53. 126931–126931.
2.
Madhi, Shabir A., Eric A. F. Simões, Nicola P. Klein, et al.. (2025). Dynamics of Respiratory Syncytial Virus Illness and Serology During Pregnancy and Infancy in the United States and South Africa. Open Forum Infectious Diseases. 12(7). ofaf386–ofaf386.
3.
Martinón‐Torres, Federico, Mika Rämet, Ryan Newton, et al.. (2025). A Phase 3B, Open-Label Study to Evaluate the Immunogenicity and Safety of the Quadrivalent Meningococcal Nimenrix® Vaccine When Given to Healthy Infants at 3 and 12 Months of Age. Infectious Diseases and Therapy. 14(2). 463–481.
4.
Peterson, James T., Jason D. Maguire, Roger Maansson, et al.. (2024). Randomized trial showing persistence of hSBA titers elicited by a pentavalent meningococcal MenABCWY vaccine for up to 4 years following a primary series and safety and immunogenicity of a booster dose. Vaccine. 43(Pt 1). 126469–126469.
5.
Peng, Yahong, et al.. (2024). A phase 3 randomized study to evaluate safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in healthy Japanese infants. International Journal of Infectious Diseases. 141. 106942–106942.
6.
Cai, Bing, Yili Chen, Beate Schmöele-Thoma, et al.. (2024). A Statistical Model to Predict Protection Against Infant Respiratory Syncytial Virus Disease Through Maternal Immunization. Vaccines. 12(12). 1351–1351.
7.
Haranaka, Miwa, Joon Young Song, Kuo‐Chin Huang, et al.. (2024). A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and Taiwan. Vaccine. 42(5). 1071–1077.
8.
Peterson, James T., Agnieszka Zareba, David Fitzpatrick, et al.. (2021). Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine. The Journal of Infectious Diseases. 225(12). 2077–2086.
9.
Essink, Brandon, James T. Peterson, Kari Yacisin, et al.. (2021). A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age. Human Vaccines & Immunotherapeutics. 17(8). 2691–2699.
10.
Klein, Nicola P., Paula Peyrani, Kari Yacisin, et al.. (2021). A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age. Vaccine. 39(38). 5428–5435.
11.
Fitzpatrick, David, Daniel A. Scott, Ingrid L. Scully, et al.. (2021). A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States. Human Vaccines & Immunotherapeutics. 17(7). 2249–2256.
12.
Schmöele-Thoma, Beate, Martin van Cleeff, Richard N. Greenberg, et al.. (2019). Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults. Human Vaccines & Immunotherapeutics. 15(3). 575–583.
13.
Thompson, Allison, Nicola P. Klein, H. Jackson Downey, et al.. (2018). Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial. Human Vaccines & Immunotherapeutics. 15(2). 444–451.
14.
Juergens, Christine, James Trammel, Yasuko Shoji, et al.. (2018). Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations. Human Vaccines & Immunotherapeutics. 14(8). 1948–1956.
15.
Juergens, Christine, Vani Sundaraiyer, Mark Cutler, et al.. (2017). Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial. Human Vaccines & Immunotherapeutics. 13(9). 2065–2071.
16.
Thompson, Allison, Douglas Girgenti, Peter C. Giardina, et al.. (2013). Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in Mexico.. PubMed. 33(6). 414–21.
17.
Lalwani, Sanjay, Ashish Bavdekar, Sundaram Balasubramanian, et al.. (2012). Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers Given With Routine Vaccines in India. The Pediatric Infectious Disease Journal. 32(5). 509–516.
18.
Galiza, Eva, Daniel A. Scott, Scott D. Patterson, et al.. (2009). Immunogenicity of booster doses of 13-valent pneumococcal conjugate and Hib/MenC vaccines given at 12 months of age in the UK. ePrints Soton (University of Southampton).
19.
Malley, Richard, Louis Vernacchio, John P. DeVincenzo, et al.. (2000). Enzyme-linked immunosorbent assay to assess respiratory syncytial virus concentration and correlate results with inflammatory mediators in tracheal secretions. The Pediatric Infectious Disease Journal. 19(1). 1–7.
20.
Gruber, William C., Gregory A. Storch, Gail J. Demmler, et al.. (1993). Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. Clinical Pharmacology & Therapeutics. 53(1). 15–21.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Michael D. Decker Breakdown of academic impact, for papers by André Charlett Breakdown of academic impact, for papers by Marek Smieja Breakdown of academic impact, for papers by William C. Blackwelder Breakdown of academic impact, for papers by Janet E. McElhaney Breakdown of academic impact, for papers by Charles G. Prober Breakdown of academic impact, for papers by B. Frank Polk Breakdown of academic impact, for papers by Adrian Egli Breakdown of academic impact, for papers by Donald P. Kotler Breakdown of academic impact, for papers by Noelle‐Angelique Molinari